INOVIO's INO-3107 Shows Promising Long-Term Reduction in Surgeries for Recurrent Respiratory Papillomatosis Patients in New Clinical Study
Reuters
Aug 11
INOVIO's INO-3107 Shows Promising Long-Term Reduction in Surgeries for Recurrent Respiratory Papillomatosis Patients in New Clinical Study
INOVIO Pharmaceuticals Inc. has announced the publication of peer-reviewed data from a retrospective study on their DNA immunotherapy, INO-3107, in The Laryngoscope. The study investigated the long-term clinical and safety response of patients with Recurrent Respiratory Papillomatosis (RRP) treated with INO-3107. Results showed a significant reduction in the number of surgeries required to manage the disease, with the Overall Response Rate improving to 86% by the end of the second year, compared to 72% at the end of the first year. The Complete Response rate increased from 28% in the first year to 50% in the second year. The mean number of surgeries needed dropped from 4.1 per year before treatment to 0.9 by the second year. Partial data extending into the third year continued to show improvement. INO-3107 was well tolerated with no serious adverse events or long-term safety issues identified.
Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Inovio Pharmaceuticals Inc. published the original content used to generate this news brief via PR Newswire (Ref. ID: PH48132) on August 11, 2025, and is solely responsible for the information contained therein.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.